吉林哪家男科医院好呢吉林小便出血是怎么回事男性,吉林最专一的男科医院地址,吉林新一代阴茎背神经控敏术,吉林市 切包皮好的医院,吉林包皮环切手术哪个比较好,吉林包皮过长手术费,吉林看前列腺炎的那个医院好

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

XICHANG, Sichuan, Aug. 12 (Xinhua) -- China launched a communications satellite PAKSAT-1R for Pakistan at 0:15 a.m. Friday from the Xichang Satellite Launch Center in southwest China's Sichuan Province.The satellite was carried by a Long March-3B carrier rocket, according to the launch center. It is China's first in-orbit delivery to Asian customers and also the first commercial satellite export to international users this year.According to statistics from the control center, the satellite successfully separated from its carrier rocket and entered geostationary transfer orbit as scheduled, 26 minutes after being launched.PAKSAT-1R will provide a range of services, including broadband Internet, telecom and broadcasting, covering some regions of Europe, South Asia, the Middle East, and the eastern Africa.The contract for the PAKSAT-1R was signed in 2008 between China Great Wall Industry Corporation and the Space and Upper Atmosphere Research Commission of Pakistan.China and Pakistan share a long history of space technology cooperation. Pakistan's first low-orbit satellite, BADR-A, was launched by China in 1990 with Long March 2E rocket.

SAN FRANCISCO, Aug. 10 (Xinhua) -- Amazon on Wednesday launched Kindle Cloud Reader, a web-based app that may help the on-line retailer to sidestep Apple's App Store restrictions.In its announcement, Amazon said Kindle Could Reader uses the HTML5 web standard to let users read e-books from their Kindle library from the Safari browser or Google's Chrome browser on their desktops or tablet, including the iPad.Support for Internet Explorer, Firefox and the Blackberry Playbook will be launched later this year.The app has a button linked to the Kindle Store, which was removed recently from the Kindle apps for iPad and iPhone.The move is taken as an answer to Apple's latest App Store restrictions, which banned developers to have any external links for purchasing digital books or subscriptions in the app, unless they give Apple a 30 percent cut from the in-app sales.Besides Amazon, Barnes & Noble, Google Books and Canadian e- book seller Kobo have also altered their iPad and iPhone apps to comply with the rules.Meanwhile, publishers and retailers have been developing web- based HTML5 apps to sidestep Apple for more control, which is an approved-of technology for iOS devices.The Financial Times, Kobo and video-on-demand service Vudu have recently launched their HTML5 app to avoid paying Apple a 30 percent cut.Industry watchers said it is unknown how Apple will deal with such apps. It would be easy for Apple to disable Web apps in the iPad's Safari browser, but the company would certainly face some backlash, said tech media website CNET.

BEIJING, Sept. 27 (Xinhuanet) -- Scientists have been making great efforts to show how harmful coffee is to us, though no evidence yet. A latest study may be reassuring for coffee-lovers.Women who drink caffeinated coffee are less likely to be depressed than those don't. And the more they drink, the lower risk of developing depression, according to a study published Monday in the Archives of Internal Medicine. Researchers of the study tracked the health of over 50,000 women aged between 30 and 55 in 1996 for a decade and recorded their mental health and coffee intake periodically.They find that women who drank two or three cups of coffee per day were 15 percent less likely than those who drank little or decaffeinated coffee to be depressed.And for those who drank four or more cups, the risk of developing depression reduced by 20 percent.The reason why coffee could protect depression is not clear. But the scientists from the Harvard University speculated that caffeine was the key player. More research is needed to show whether caffeine can ward off depression.It might be that not-depressed people tended to be more activated and the habit of coffee drinking just fit in their lifestyle.However, the depressed ones, who might suffer from sleeplessness, chose not to drink coffee because the caffeine might exacerbate it."There's no need to start drinking coffee," said Dr. Alberto Ascherio, the senior author of the study, "The message is that coffee is safe to drink, with no adverse effects. That's really all that can be said."

BEIJING, July 20 (Xinhuanet) -- Some U.S. soldiers returning from the Middle East have acquired constrictive bronchiolitis, a kind of lung damage virtually unknown in young adults, according to U.S. News & World Report."Respiratory disorders are emerging as a major consequence of service in southwest Asia," said study author Dr. Matthew S. King, an assistant professor of pulmonary and critical care at Meharry Medical College in Nashville, Tenn."In addition to our study, there have been studies showing increases in asthma, obstructive lung disease, allergic rhinitis and a general increase in reports of respiratory symptoms," he added. "Most of the patients say they can’t seem to catch their breath when exerting themselves."On the other hand, Anthony Szema, a physician and engineer at Stony Brook University in New York, has examined a soldier and found tiny complexes of titanium and iron in the man’s lungs, where metals can cause severe damage.Mined separately, the two metals could have gotten together only through a manufacturing process, Szema reported. While the metals’ origin is unclear, he presents a new case study, suspecting garbage-burning pits or exploding devices sent them airborne.While the cases in the study represent only a few dozen people of the hundreds of thousands serving in the Middle East, there is no estimate of how many more might have bronchiolitis.it is recommended that soldiers exercise caution in the field until more is known. Soldiers are now told to wear a mask when burning garbage.